ABBOTT PARK, Ill., Jan. 17, 2019
/PRNewswire/ -- Abbott (NYSE: ABT) announced today that it has been
selected by the Japanese Red Cross Society (JRC) to partner in
screening the country's blood donations. The 8-year contract is for
the exclusive supply of serological instrumentation, tests and
consumables used for blood and plasma screening. The JRC screens
approximately 5 million blood donations each year, helping ensure a
safe supply of products needed for blood transfusions and plasma
therapies. Abbott's broad portfolio of products is used to screen
more than 60 percent of the world's blood and plasma supply.
This agreement was reached after an extensive evaluation by the
JRC of commercially available products across numerous analytical
and quality parameters. As part of the proposal, Abbott will
provide the JRC with Abbott's technology, leveraging the company's
decades of leadership in blood screening for infectious diseases,
medical and scientific research and expertise in efficiency through
lab automation. The JRC will screen each donation across eight
distinct assays, including hepatitis and retrovirus analysis.
"Abbott is excited and proud to enter into a long-term
partnership with the Japanese Red Cross, a global leader in blood
and plasma screening," said Lou
Morrone, Vice President, Transfusion Medicine, Abbott. "This
new collaboration will allow us to deliver proven technology to
support them in their important mission of protecting patients by
helping ensure the safety of their blood and plasma supply."
About the Japanese Red Cross Society
The Japanese Red
Cross Society, in cooperation with the national government and
local authorities, promotes nationwide blood donation to ensure a
continuous supply of the blood products that are essential for
medical treatment. Through the generous cooperation of
approximately 5 million people, the JRC secures required quantities
of blood products and delivers them to medical institutions across
the country.
About Abbott
At Abbott, we're committed to helping
people live their best possible life through the power of health.
For more than 125 years, we've brought new products and
technologies to the world -- in nutrition, diagnostics, medical
devices and branded generic pharmaceuticals -- that create more
possibilities for more people at all stages of life. Today, 99,000
of us are working to help people live not just longer, but better,
in the more than 150 countries we serve.
Connect with us at www.abbott.com, on Facebook
at www.facebook.com/Abbott and on Twitter @AbbottNews and
@AbbottGlobal.
View original
content:http://www.prnewswire.com/news-releases/japanese-red-cross-society-selects-abbott-technology-to-screen-countrys-blood-and-plasma-supply-300779116.html
SOURCE Abbott